Clinical Trial Update: Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 imaging-focused trial evaluating how imaging of integrins αvβ3 relates to characterizing residual masses in non-seminomatous germ cell tumors after ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-seminomatous Germ Cell Tumor

Snippet

Sponsor: Centre Francois Baclesse | Conditions: Non-seminomatous Germ Cell Tumors, Metastasis | Phase 2 | Status: COMPLETED